MENU

SNDX Stock Syndax Pharmaceuticals (SNDX, $11.93) entered Uptrend as Momentum indicator ascends above 0 level on Apr 21, 2025

A.I.dvisor
at Tickeron.com
Loading...
SNDX - Syndax Pharmaceuticals
Momentum signal
Bullish Trend
Odds of UP Trend
Tickeron
Momentum signal
Price: $11.93
Daily change: +$0.39 (+3.38%)
Daily volume: 2.5M
Industry: Biotechnology
This indicator may be signaling that SNDX's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 82 similar cases where SNDX's Momentum Indicator exceeded 0, and of them led to a successful outcome. Odds of Success:

SNDX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SNDX turned positive on April 17, 2025. Looking at past instances where SNDX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SNDX's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 21, 2025. You may want to consider a long position or call options on SNDX as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SNDX entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SNDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.858) is normal, around the industry mean (13.887). P/E Ratio (0.000) is within average values for comparable stocks, (63.180). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.782). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (46.729) is also within normal values, averaging (251.479).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals for novel cancer therapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
35 Gatehouse Drive
Phone
+1 781 419-1400
Employees
184
Web
https://www.syndax.com